iX Biopharma Advances Wafermine Out-Licensing, Starts Preclinical Trials for iXB 401

MT Newswires

2024/09/17

iX Biopharma (SGX:42C) has updated its progress on Wafermine and iXB 401, according to a Monday filing on the Singapore Exchange.

Following the end of its licensing agreement with Seelos Therapeutics, iX Biopharma has engaged Kybora, a global life sciences advisory firm, to assist in out-licensing Wafermine, a sublingual ketamine wafer.

Kybora will help the company explore licensing opportunities in key markets for Complex Regional Pain Syndrome (CRPS) and depressive disorders. Wafermine's Orphan Drug Designation from the US FDA emphasizes its potential as a non-opioid treatment option.

The company has also begun preclinical testing for iXB 401, a sublingual semaglutide wafer for Type 2 diabetes and obesity.

iX Biopharma has developed various formulations and appointed a clinical research organization to conduct studies in diabetic mice. iXB 401 aims to improve patient compliance and address supply and environmental challenges associated with current GLP-1 treatments.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2468801165"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2468801165\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2468801165?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-17 10:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468801165","market":"sg","top_or_hot":-1,"title":"iX Biopharma Advances Wafermine Out-Licensing, Starts Preclinical Trials for iXB 401","media":"MT Newswires","content":"<html><body><p> iX Biopharma (SGX:42C) has updated its progress on Wafermine and iXB 401, according to a Monday filing on the Singapore Exchange.</p><p>Following the end of its licensing agreement with Seelos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, iX Biopharma has engaged Kybora, a global life sciences advisory firm, to assist in out-licensing Wafermine, a sublingual ketamine wafer.</p><p>Kybora will help the company explore licensing opportunities in key markets for Complex Regional Pain Syndrome (CRPS) and depressive disorders. Wafermine's Orphan Drug Designation from the US FDA emphasizes its potential as a non-opioid treatment option.</p><p>The company has also begun preclinical testing for iXB 401, a sublingual semaglutide wafer for Type 2 diabetes and obesity.</p><p>iX Biopharma has developed various formulations and appointed a clinical research organization to conduct studies in diabetic mice. iXB 401 aims to improve patient compliance and address supply and environmental challenges associated with current GLP-1 treatments.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>iX Biopharma Advances Wafermine Out-Licensing, Starts Preclinical Trials for iXB 401</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\niX Biopharma Advances Wafermine Out-Licensing, Starts Preclinical Trials for iXB 401\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1060499803\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires </p>\n<p class=\"h-time smaller\">2024-09-17 10:41</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> iX Biopharma (SGX:42C) has updated its progress on Wafermine and iXB 401, according to a Monday filing on the Singapore Exchange.</p><p>Following the end of its licensing agreement with Seelos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, iX Biopharma has engaged Kybora, a global life sciences advisory firm, to assist in out-licensing Wafermine, a sublingual ketamine wafer.</p><p>Kybora will help the company explore licensing opportunities in key markets for Complex Regional Pain Syndrome (CRPS) and depressive disorders. Wafermine's Orphan Drug Designation from the US FDA emphasizes its potential as a non-opioid treatment option.</p><p>The company has also begun preclinical testing for iXB 401, a sublingual semaglutide wafer for Type 2 diabetes and obesity.</p><p>iX Biopharma has developed various formulations and appointed a clinical research organization to conduct studies in diabetic mice. iXB 401 aims to improve patient compliance and address supply and environmental challenges associated with current GLP-1 treatments.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6506","symbol_name":"製藥與醫學研究概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2468801165","we_media_id":"1060499803","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468801165","pubTimestamp":1726540898,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"MT Newswires","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1060499803","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"iX Biopharma  has updated its progress on Wafermine and iXB 401, according to a Monday filing on the Singapore Exchange.Following the end of its licensing agreement with Seelos Therapeutics, iX Biopharma has engaged Kybora, a global life sciences advisory firm, to assist in out-licensing Wafermine, a sublingual ketamine wafer.Kybora will help the company explore licensing opportunities in key markets for Complex Regional Pain Syndrome  and depressive disorders. Wafermine's Orphan Drug Designation from the US FDA emphasizes its potential as a non-opioid treatment option.The company has also begun preclinical testing for iXB 401, a sublingual semaglutide wafer for Type 2 diabetes and obesity.iX Biopharma has developed various formulations and appointed a clinical research organization to conduct studies in diabetic mice. iXB 401 aims to improve patient compliance and address supply and environmental challenges associated with current GLP-1 treatments.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK6506":"制药与医学研究概念","BK6079":"制药","42C.SI":"IX生物制药"},"translate_title":"iX Biopharma推进Wafermine外包许可，开始iXB 401的临床前试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"42C.SI":0.9},"content_text":"iX Biopharma (SGX:42C) has updated its progress on Wafermine and iXB 401, according to a Monday filing on the Singapore Exchange.Following the end of its licensing agreement with Seelos Therapeutics, iX Biopharma has engaged Kybora, a global life sciences advisory firm, to assist in out-licensing Wafermine, a sublingual ketamine wafer.Kybora will help the company explore licensing opportunities in key markets for Complex Regional Pain Syndrome (CRPS) and depressive disorders. Wafermine's Orphan Drug Designation from the US FDA emphasizes its potential as a non-opioid treatment option.The company has also begun preclinical testing for iXB 401, a sublingual semaglutide wafer for Type 2 diabetes and obesity.iX Biopharma has developed various formulations and appointed a clinical research organization to conduct studies in diabetic mice. iXB 401 aims to improve patient compliance and address supply and environmental challenges associated with current GLP-1 treatments.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}